| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
112,419 | 51,769 | 21,226 | 8,403 | |||
General and administrative | ||||||
57,182 | 39,894 | 22,038 | 2,449 | |||
Total operating expenses | ||||||
169,601 | 91,663 | 43,264 | 10,852 | |||
Loss from operations | ||||||
-169,601 | -91,663 | -43,264 | -10,852 | |||
Other income (expense): | ||||||
Interest income | ||||||
7,994 | 5,078 | 584 | - | |||
Interest expense | ||||||
2,590 | 464 | 309 | 149 | |||
Change in fair value of preferred stock warrant liability | ||||||
- | 2,187 | 785 | -1 | |||
Other income (expense), net | ||||||
739 | 41 | -73 | - | |||
Interest income and other income, net | ||||||
- | - | - | -16 | |||
Total other income (expense), net | ||||||
6,143 | 2,468 | -583 | -164 | |||
Net loss | ||||||
-163,458 | -89,195 | -43,847 | -11,016 | |||
Accretion of Series A redeemable convertible preferred stock to redemption value | ||||||
- | - | 656 | 748 | |||
Net loss attributable to common stockholders | ||||||
-163,458 | -89,195 | -44,503 | -11,764 | |||
Net loss per share, basic and diluted | ||||||
-2.08 | -2.27 | -5.55 | -1.63 | |||
Weighted average common shares outstanding, basic and diluted | ||||||
78,688 | 39,285 | 8,023 | 7,200 | |||
Comprehensive loss: | ||||||
Net loss | ||||||
-163,458 | -89,195 | -43,847 | -11,016 | |||
Other comprehensive income (loss): | ||||||
Unrealized gains (losses) on investments, net of tax of $0 | ||||||
104 | -29 | - | - | |||
Comprehensive loss | ||||||
-163,354 | -89,224 | -43,847 | -11,016 | |||